• Skip to main content

Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

This page tracks new and upcoming treatment options for Parkinson’s disease (PD). What’s in development? What’s promising? What’s available soon? Current topics include BIIB094, BIIB054, NLY01, DNL151, YTX-7739, MCC950, GDNF, gene therapy, LRRK2, and more. Jump to section: News, Research, Clinical Trials

Last updated: 5 years ago
Subscribe

News

  • Stem cells can repair Parkinson’s-damaged circuits in mouse brains Sep 25, 2020
  • Parkinson’s disease is not one, but two diseases Sep 22, 2020
  • Leading-edge technology unmasks protein linked to Parkinson’s disease Aug 19, 2020
  • Epigenomic Master Regulator Enzyme Protects Against Parkinson’s Disease Aug 18, 2020
  • T-006 is a potent neuroprotective and neuroregenerative agent that may have therapeutic potential in the treatment of Parkinson’s, study finds Jul 24, 2020
  • The Stanford Parkinson’s Disease Plasma Study – The Science of Parkinson’s Jul 8, 2020
  • Pilot study suggests Parkinson’s disease progression can be slowed Jun 30, 2020
  • Solving a Parkinson’s disease puzzle through protein design: breakthrough will open up a new dimension in drug discovery for Parkinson’s disease Jun 11, 2020
  • Scientists Turned Parkinson’s Disease Patient’s Skin Cells Into Brain Cells Now He Can Tie His Shoes Again May 14, 2020
  • A secret experiment revealed: In a medical first, doctors treat Parkinson’s with a novel brain cell transplant May 12, 2020
  • UGA researchers report possible breakthrough in Parkinson’s treatment Mar 17, 2020
  • Molecule BT13 offers hope for halting Parkinson’s: has potential to boost dopamine levels and protect dopamine-producing brain cells from dying Feb 14, 2020
  • San Diego biotech uses advanced stem cell techniques in hopes of rolling back the clock on Parkinson’s symptoms Dec 13, 2019
  • New Molecular Drivers of Parkinson Disease Discovered, Indicating Potential Treatment Innovations Nov 20, 2019
  • Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype? Nov 15, 2019
  • Parkinson Disease Shown to Induce Immune Imbalance in the Blood, Indicating Possible Benefit of Immune Modulation Nov 4, 2019
  • Parkinson’s inhibitor enzyme presents natural therapeutic opportunity Nov 1, 2019
  • Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson’s disease Oct 16, 2019
  • Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease Oct 7, 2019
  • Scientists find potential diagnostic tool, treatment for Parkinson’s disease Sep 26, 2019
  • Phase 2 Trial of Gene Therapy, VY-AADC02, for Advanced Parkinson’s Enrolling in US Sep 24, 2019
  • In Mice and Men, Prostate Drug Reportedly Treats Parkinson’s Disease Sep 20, 2019
  • Prostate drug (terazosin) may slow Parkinson’s disease Sep 17, 2019
  • Scientists listed ways of applying genetic engineering (CRISPR) to treat Parkinson’s disease Sep 10, 2019
  • Engineered Protein Binds to Alpha-synuclein to Prevent Toxic Clumping, Study Reports Sep 9, 2019
  • Biogen begins recruiting patients for phase 1 clinical trial of BIIB094 for Parkinson’s disease Sep 4, 2019
  • Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease Sep 3, 2019
  • Nourianz Approved in US as Add-on Therapy to Carbidopa/Levodopa to Treat Off Periods in Parkinson’s Aug 29, 2019
  • FDA approves new add-on drug to treat off episodes in adults with Parkinson’s disease Aug 27, 2019
  • Deep brain stimulation eases Parkinson’s disease symptoms by boosting dopamine Aug 21, 2019
  • Could estrogen help treat Parkinson’s? Aug 13, 2019
  • Discovery could lead to new treatments for Parkinson’s, other brain diseases: Study reveals crucial role of alpha-synuclein protein in DNA repair Jul 29, 2019
  • Two brain chemicals should be targeted in Parkinson’s treatment, study says Jul 17, 2019
  • Nobiletin, a citrus flavonoid, has the potential to become a novel drug for the treatment of Parkinson’s, according to researchers in Japan Jul 13, 2019
  • Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson’s Disease Jul 10, 2019
  • Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation, Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019 Jul 8, 2019
  • Could this newly discovered protein help treat Parkinson’s? Jul 3, 2019
  • Dundee partners with Bukwang Pharm to develop new treatment for Parkinson’s Jul 2, 2019
  • Emerald Health Pharmaceuticals Demonstrates Neuroprotective Activity of Novel Cannabigerol Derivatives in Huntington’s and Parkinson’s Disease Models Jul 2, 2019
  • Charity invests £1 million to develop a treatment to slow down progression of Parkinson’s Jul 1, 2019
  • Parkinson’s, Alzheimer’s, and the New Science of Hope Jun 29, 2019
  • A trial has begun in the US for the ENT-01 therapy treatment of Parkinson’s, with the first patient enrolled Jun 28, 2019
  • Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University Jun 27, 2019
  • Scientists track Parkinson’s journey from gut to brain in mice Jun 26, 2019
  • Four New Funded Studies Use Data to Identify Parkinson’s Prevention or Treatment Options Jun 18, 2019
  • Gut microbes interfere with Parkinson’s drug – but we could stop them Jun 13, 2019
  • Scientists identify potential target for Parkinson’s treatment Jun 12, 2019
  • Neurocrine Biosciences to Present Data on Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders Jun 11, 2019
  • Australian trial gives new hope for Parkinson’s disease treatment Jun 11, 2019
  • Parkinson’s: New gene therapy shows promise for prevention Jun 7, 2019
  • Stopping Parkinson’s disease before it starts Jun 7, 2019
  • Biogen Initiates Phase 1 Study of BIIB094 in Patients with Parkinson’s Disease Jun 6, 2019
  • Ultrasound method restores dopaminergic pathway in brain at Parkinson’s early stages Jun 6, 2019
  • Promising molecule [anle138b] targets protein to offer hope for people with Parkinson’s Jun 5, 2019
  • UCB Initiates Phase 1b US-Based Multicenter Clinical Trial in Parkinson’s Disease Patients with UCB0599, a Compound Arising from the Neuropore-UCB Collaboration May 28, 2019
  • Duke symposium brings together global experts to understand and develop treatments for Parkinson’s disease May 23, 2019
  • Stopping inflammation in its tracks: A leap forward for new anti-inflammatory drugs [MCC950] May 13, 2019
  • Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients May 5, 2019
  • Parkinson’s disease spinal stimulation treatment restores movement – study Apr 23, 2019
  • Parkinson’s implant ‘boosts the ability to walk’ as cutting edge treatment restores movement to patients who were previously left housebound Apr 22, 2019
  • Parkinson’s results beyond researchers’ wildest dreams Apr 22, 2019
  • Small Trial Provides New Hope Against Parkinson’s Disease Mar 1, 2019
  • New Treatment Offers Potentially Promising Results for the Possibility of Slowing, Stopping, or Even Reversing Parkinson’s Disease Feb 27, 2019
  • Gut Bacteria Influence the Efficacy of a Parkinson’s Drug Jan 19, 2019

Research

  • Asparagine endopeptidase inhibitor protects against fenpropathrin-induced neurodegeneration via suppressing α-synuclein aggregation and neuroinflammation Sep 21, 2020
  • Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction Aug 19, 2020
  • Gene Therapy in the Management of Parkinson’s Disease: Potential of GDNF as a Promising Therapeutic Strategy Aug 17, 2020
  • Recent developments in the treatment of Parkinson’s Disease Jul 31, 2020
  • Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson’s disease models through activating the MEF2-PGC1α and BDNF/CREB pathways Jul 24, 2020
  • Identifying and predicting Parkinson’s disease subtypes through trajectory clustering via bipartite networks Jun 17, 2020
  • Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson’s disease Jun 2, 2020
  • Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases such as Parkinson’s disease Apr 28, 2020
  • Glucocerebrosidase as a Therapeutic Target for Parkinson’s Disease Feb 27, 2020
  • NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy Jan 3, 2020
  • Neuroprotective effects of Bacopa monnieri in Parkinson’s disease model Dec 13, 2019
  • Blocking CXCL12/CXCR4 may be a potential therapeutic approach for Parkinson’s disease progression Dec 12, 2019
  • Targeting the microglial NLRP3 inflammasome and its role in Parkinson’s disease Nov 4, 2019
  • Systemic activation of Nrf2 pathway in Parkinson’s disease Nov 4, 2019
  • Editorial: Peripheral Immunity in Parkinson’s Disease: Emerging Role and Novel Target for Therapeutics Oct 15, 2019
  • Targeting BDNF signaling by natural products: novel synaptic repair therapeutics for neurodegeneration and behavior disorders Sep 20, 2019
  • Mitochondrial CHCHD2 and CHCHD10: Roles in Neurological Diseases and Therapeutic Implications Sep 16, 2019
  • Protective and Regenerative Roles of T Cells in Central Nervous System Disorders Sep 12, 2019
  • Essential role of phosphodiesterase 7 (PDE7) enzyme in neurodegeneration and inflammatory-mediated brain damage opens door to new therapeutic interventions for Parkinson’s disease Aug 31, 2019
  • Hepcidin and its therapeutic potential in neurodegenerative disorders Aug 30, 2019
  • Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson’s Disease Aug 14, 2019
  • The gut microbiota: A novel therapeutic target in Parkinson’s disease? Aug 12, 2019
  • P1 Receptor Agonists/Antagonists – Potential Parkinson’s Drug Candidates of the Future Jul 16, 2019
  • Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator Jul 11, 2019
  • Cysteamine as a novel disease-modifying compound for Parkinson’s disease: Over a decade of research supporting a clinical trial Jul 10, 2019
  • Potential Benefits of Nobiletin, A Citrus Flavonoid, against Parkinson’s Disease Jul 10, 2019
  • Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease Jul 10, 2019
  • The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson’s disease Jul 10, 2019
  • Recently identified therapeutic targets in dystonia based on recent preclinical animal studies and clinical trials investigating novel therapeutics Jul 4, 2019
  • Protein glycation: An emerging new medicinal target area for Parkinson’s disease Jul 3, 2019
  • Modulation of TMEM175 may impact α-synuclein biology and therefore may be a rational therapeutic strategy for PD Jul 2, 2019
  • Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson’s disease patient fibroblasts Jul 1, 2019
  • Recent advances of induced pluripotent stem cells application in neurodegenerative diseases Jun 27, 2019
  • Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease Jun 26, 2019
  • α-Synuclein in Parkinson’s disease: causal or bystander? Jun 25, 2019
  • Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson’s disease in mice Jun 25, 2019
  • Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism Jun 14, 2019
  • Gut microbes metabolize Parkinson’s disease drug Jun 14, 2019
  • Amelioration of the nigrostriatal pathway facilitated by ultrasound-mediated neurotrophic delivery in early Parkinson’s disease Jun 10, 2019
  • Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease Jun 4, 2019
  • Defining α-synuclein species responsible for Parkinson disease phenotypes in mice May 29, 2019
  • Focused ultrasound opening of the blood-brain barrier for treatment of Parkinson’s disease May 28, 2019
  • Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease May 21, 2019
  • Lysosomal exocytosis is a potential therapeutic target in Parkinson’s and other diseases characterized by the accumulation of a-synuclein May 16, 2019
  • Targeting kinases in Parkinson’s disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium May 15, 2019
  • MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition [abstract-only] May 13, 2019
  • PDZ Scaffold Protein CAL Couples with Metabotropic Glutamate Receptor 5 to Protect Against Cell Apoptosis and Is a Potential Target in the Treatment of Parkinson’s Disease May 9, 2019
  • FTY720 may reduce Parkinson’s disease progression by inhibiting NLRP3 inflammasome activation May 8, 2019
  • Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia May 6, 2019
  • Marine-Derived Natural Compounds for the Treatment of Parkinson’s Disease Apr 11, 2019
  • Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson’s Disease Mar 27, 2019
  • Histamine N-Methyltransferase in the Brain Feb 10, 2019
  • The Potential of L-Type Calcium Channels as a Drug Target for Neuroprotective Therapy in Parkinson’s Disease Jan 6, 2019

Clinical Trials

  • A Clinical Study of NLY01 in Patient’s With Early Parkinson’s Disease Aug 18, 2020
  • Microbiota Intervention to Change the Response of Parkinson’s Disease Aug 14, 2020
  • A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease Aug 5, 2020
  • Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson’s Disease Jul 9, 2020
  • Simvastatin as a Neuroprotective Treatment for Moderate Parkinson’s Disease Jun 1, 2020
  • TSPO-PET for Neuroinflammation in Parkinson’s Disease Apr 27, 2020
  • A Phase 3 Study With P2B001 in Subjects With Early Parkinson’s Mar 10, 2020
  • Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson’s Disease Feb 27, 2020
  • Brain Bioenergetics in Parkinson’s Disease and Response to Repeated Oral UDCA Treatment Nov 1, 2019
  • A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease Nov 1, 2019
  • Transplantation of Neural Stem Cell-Derived Neurons for Parkinson’s Disease Sep 26, 2019
  • Study to Evaluate APL-130277 in Subjects With Parkinson’s Disease Complicated by Motor Fluctuations Sep 25, 2019
  • Extension Study of Ampreloxetine (TD-9855) for Treating snOH in Subjects With Primary Autonomic Failure Sep 19, 2019
  • Study to Evaluate DNL151 in Subjects With Parkinson’s Disease Sep 18, 2019
  • A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson’s Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 Sep 18, 2019
  • Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson’s Disease Sep 16, 2019
  • Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson’s Disease Sep 4, 2019
  • Study of UB-312 in Healthy Participants and Parkinson’s Disease Patients Aug 30, 2019
  • Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson’s Disease Aug 30, 2019
  • SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis Aug 13, 2019
  • Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson’s Disease Jul 3, 2019
  • A Clinical Trial Investigating the Efficacy, Safety and Tolerability of ND0612 Infusion in Subjects With Parkinson’s Disease Experiencing Motor Fluctuations Jul 3, 2019
  • Dose Escalation Study of Cu(II)ATSM in Parkinson’s Disease Jun 25, 2019
  • Trial of Ursodeoxycholic Acid (UDCA) for Parkinson’s Disease: The “UP” Study Jun 11, 2019
  • Chronic Effects of DBS in Parkinson’s Disease and Dystonia Jun 5, 2019
  • BTRX-246040 Study in Subjects With Parkinson’s Disease With Motor Fluctuations [Completed] Jun 5, 2019
  • Study to Evaluate DNL201 in Subjects With Parkinson’s Disease Jun 5, 2019
  • Clinical Trial to Evaluate the Safety and Tolerability of Molecular Hydrogen in Patients With Parkinson’s Disease Jun 3, 2019
  • Effects of Lingzhi (Ganoderma) on Disease Progression in Patients With Untreated Early Parkinson’s Disease May 29, 2019
  • A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation May 22, 2019
  • A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson’s Disease and Cognitive Impairment May 22, 2019
  • Modulation of Gut Microbiota by Rifaximin in PD Patients May 22, 2019
  • Safety and Efficacy of THN102 in Patients With Parkinson’s Disease and Excessive Daytime Sleepiness May 21, 2019
  • VY-AADC02 for Parkinson’s Disease With Motor Fluctuations May 20, 2019
  • A Phase 1 Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects May 17, 2019
  • A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson’s Disease Patients With Motor Fluctuations May 16, 2019
  • A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson’s Disease May 15, 2019
  • Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson’s Disease May 13, 2019
  • Single Ascending Dose Study of MEDI1341 in Healthy Volunteers May 13, 2019
  • See also: Fox Trial Finder – The Michael J. Fox Foundation

Projects

Discussion

  • Parkinson’s Disease – Reddit
  • Parkinson’s Forum UK
  • Parkinson’s Disease Caregiver Forum
  • Daily Strength – Parkinson’s Disease Support Group
  • Parkinson’s Foundation Forum

Powered by Urgent Research

Copyright © 2025 Urgent Research